«

»

ICARE Social Media Post June 2020

Advances in Treatment for Colorectal Cancer

image_print

On June 29, 2020, the FDA approved the use of Keytruda (pembrolizumab), as first-line treatment in unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer.

Among people with Lynch syndrome, the risk for colorectal cancer (which often has microsatellite instability and/or mismatch-repair deficiency) is raised.

Keytruda (pembrolizumab) showed to double the progression-free survival in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer.

The recent FDA approval to use Keytruda (pembrolizumab) as first-line treatment for microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer represents another strategy to improve treatment of individuals with Lynch syndrome and unresectable or metastatic colorectal cancer.

Check out the news release: https://www.fda.gov/news-events/press-announcements/fda-approves-first-line-immunotherapy-patients-msi-hdmmr-metastatic-colorectal-cancer

Permanent link to this article: https://inheritedcancer.net/post63020/